Salvage radiotherapy for locoregional recurrence of esophageal cancer after surgery
- 6 September 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 55 (1) , 59-66
Abstract
Objective: There is no consensus on the optimal treatment for patients with locoregional recurrence of esophageal cancer after surgery. The objective of this study was to investigate the outcomes and prognostic factors associated with salvage radiotherapy in patients with locoregional recurrence of esophageal cancer after surgery. Methods: We reviewed 80 patients with locoregional recurrence of esophageal cancer after surgery who were treated with radiotherapy. The median dose was 60 Gy, and 29 patients (36%) received elective nodal irradiation. Fifty-three patients (66%) received concurrent chemotherapy (mostly 5-fluorouracil and cisplatin) during radiotherapy. Overall survival, progression-free survival and in-field recurrence rate were assessed. Results: The median follow-up period was 17 months. Two-year overall survival, progression-free survival and in-field recurrence rate were 50.3%, 23.5% and 41.3%, respectively. On multivariate analysis, a maximum diameter of locoregional recurrence lesions 14 months was associated with higher PFS (P = 0.003). Late grade 3 toxicities occurred in three patients (3.8%). No grade 4 or higher toxicity was observed. Conclusions: Salvage radiotherapy demonstrated efficacy in achieving in-field control with acceptable toxicity. However, the high rate of out-of-field metastases led to poor progression-free survival and overall survival, particularly in cases involving large lesions and a short disease-free interval. A prospective study is warranted to establish a treatment strategy, particularly considering the combined use of effective anti-cancer drugs.Keywords
This publication has 44 references indexed in Scilit:
- Cardiovascular adverse events associated with immune checkpoint inhibitors: A retrospective multicenter cohort studyCancer Medicine, 2024
- Incident Atrial Fibrillation and Survival Outcomes in Esophageal Cancer following RadiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2023
- Patterns of failure after salvage chemoradiotherapy for postoperative loco-regional recurrent esophageal cancer: 20-year experience in a single institution in JapanEsophagus, 2022
- Cardiotoxicity of radiation therapy in esophageal cancerReports of Practical Oncology and Radiotherapy, 2020
- Comparison of the effects of radiotherapy doses of 50.4 Gy and 60 Gy on outcomes of chemoradiotherapy for thoracic esophageal cancer: subgroup analysis based on the Comprehensive Registry of Esophageal Cancer in Japan from 2009 to 2011 by the Japan Esophageal SocietyEsophagus, 2020
- Propensity Score-based Comparison of Long-term Outcomes With 3-Dimensional Conformal Radiotherapy vs Intensity-Modulated Radiotherapy for Esophageal CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Long-Term Results of Radiochemotherapy for Solitary Lymph Node Metastasis After Curative Resection of Esophageal CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Radiotherapy With or Without Concurrent Chemotherapy for Lymph Node Recurrence After Radical Surgery of Thoracic Esophageal Squamous Cell CarcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Surgical Outcomes in Esophageal Cancer Patients with Tumor Recurrence After Curative EsophagectomyJournal of Gastrointestinal Surgery, 2007
- Pattern of Recurrence after Extended Radical Esophagectomy with Three‐Field Lymph Node Dissection for Squamous Cell Carcinoma in the Thoracic EsophagusWorld Journal of Surgery, 1997